Published in Indian J Urol on December 03, 2009
Assessment of intratumoral micromorphology for patients with clear cell renal cell carcinoma using susceptibility-weighted imaging. PLoS One (2013) 0.80
Development and characterization of a novel mAb against bilitranslocase - a new biomarker of renal carcinoma. Radiol Oncol (2013) 0.79
Standard b-value versus low b-value diffusion-weighted MRI in renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer (2014) 0.76
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model. Oncotarget (2016) 0.75
Correlation between BOLD-MRI and HIF expression level in renal carcinoma. Int J Clin Exp Pathol (2015) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Rising incidence of renal cell cancer in the United States. JAMA (1999) 9.57
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46
The changing natural history of renal cell carcinoma. J Urol (2001) 4.72
Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol (2000) 4.72
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol (2002) 3.52
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
The results of radical nephrectomy for renal cell carcinoma. J Urol (1969) 3.37
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol (2000) 3.26
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol (2002) 2.43
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol (2005) 2.30
Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol (2005) 2.30
Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A (2001) 2.22
Prognostic factors in metastatic renal carcinoma. J Urol (1986) 2.18
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol (2000) 2.06
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol (2005) 1.89
Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol (1997) 1.89
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res (1988) 1.84
TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 1.80
Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg (1989) 1.71
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol (1999) 1.67
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients. Eur Urol (2005) 1.62
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol (2005) 1.60
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol (2005) 1.55
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol (2007) 1.53
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A (2003) 1.53
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol (2003) 1.52
Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol (2007) 1.52
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol (2004) 1.52
Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res (2004) 1.51
Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology (2005) 1.47
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol (1996) 1.47
Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int (2005) 1.45
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer (2005) 1.43
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol (2005) 1.42
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol (2005) 1.42
Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol (1991) 1.35
Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol (2004) 1.33
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer (2003) 1.29
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol (2003) 1.25
Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep (2005) 1.25
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol (2005) 1.24
Prognostic significance of the mode of detection in renal tumours. BJU Int (2002) 1.17
Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J Urol (1995) 1.17
Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol (1984) 1.16
Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol (1996) 1.16
Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol (2007) 1.15
Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol (2000) 1.15
Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol (2004) 1.12
Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol (2003) 1.12
Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol (2004) 1.11
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol (2001) 1.11
Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol (1987) 1.10
Classification of renal neoplasms based on molecular signatures. J Urol (2006) 1.09
Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol (2003) 1.08
The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int (2003) 1.08
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol (2006) 1.08
Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol (1996) 1.07
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol (2006) 1.06
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology (2005) 1.04
Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol (2005) 1.02
TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol (2003) 1.02
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer (2005) 1.02
Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer (2005) 1.00
Renal cell carcinoma with extension into the inferior vena cava: problems in diagnosis, staging and treatment. Eur Urol (1992) 0.99
Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol (2004) 0.98
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol (2007) 0.98
Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol (2006) 0.92
pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol (2005) 0.90
Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol (2001) 0.89
Gene expression profiling of renal cell carcinoma. Clin Cancer Res (2004) 0.89
Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res (2004) 0.88
Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol (2004) 0.88
Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol (1990) 0.87
Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm. J Urol (2001) 0.86
Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer (2007) 0.85
Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer (2007) 0.83
Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer (2005) 0.82
Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol (1958) 0.82
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol (2009) 2.37
Color Doppler sonography reliably identifies testicular torsion in boys. Urology (2009) 1.95
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer (2011) 1.64
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Three-dimensional vs standard laparoscopy: comparative assessment using a validated program for laparoscopic urologic skills. Urology (2013) 1.56
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol (2009) 1.54
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer (2008) 1.53
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol (2009) 1.52
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Prospective randomized multicenter study comparing prostate cancer detection rates of end-fire and side-fire transrectal ultrasound probe configuration. Urology (2012) 1.46
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
High-risk human papilloma virus infection of the foreskin in asymptomatic boys. Urology (2013) 1.39
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer (2008) 1.32
Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther (2008) 1.27
Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer (2010) 1.18
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol (2013) 1.18
Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol (2007) 1.13
External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery. World J Urol (2010) 1.08
Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int (2013) 1.07
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol (2006) 1.06
Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer (2011) 0.99
Importance of surgical margins in the management of renal cell carcinoma. Nat Clin Pract Urol (2008) 0.99
Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int (2007) 0.98
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol (2007) 0.98
Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol (2014) 0.98
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Laparoscopic nephron sparing surgery: a multi-institutional European survey of 592 cases. Arch Ital Urol Androl (2008) 0.95
Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol (2012) 0.91
Less smoke and minimal tissue carbonization using a thulium laser for laparoscopic partial nephrectomy without hilar clamping in a porcine model. J Endourol (2007) 0.91
Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol (2012) 0.90
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer (2013) 0.88
Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol (2007) 0.88
Contemporary urologic minilaparoscopy: indications, techniques, and surgical outcomes in a multi-institutional European cohort. J Endourol (2014) 0.88
Standardized linear port configuration to improve operative ergonomics in laparoscopic renal and adrenal surgery: experience with 1264 cases. J Endourol (2011) 0.88
Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC). BJU Int (2014) 0.86
Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience. World J Urol (2012) 0.84
Interpersonal variability and present diagnostic dilemmas in Bosniak classification system. Scand J Urol Nephrol (2011) 0.84
Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol (2010) 0.84
Laparoscopic renal surgery for benign disease. Curr Urol Rep (2007) 0.84
Sex steroids and gender differences in nonmuscle invasive bladder cancer. Curr Opin Urol (2014) 0.84
Management of single large nonstaghorn renal stones in the CROES PCNL global study. J Urol (2012) 0.84
Nephrometry scoring systems for surgical decision-making in nephron-sparing surgery. Curr Opin Urol (2014) 0.82
Laser endoureterotomy and endopyelotomy: an update. World J Urol (2014) 0.82
Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? Curr Opin Urol (2015) 0.82
FloSeal reduces the incidence of lymphoceles after lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy. J Endourol (2011) 0.82
Laparoendoscopic single-site porcine nephrectomy using a novel valveless trocar system. J Endourol (2010) 0.82
Complex renal cystic masses: current standards and controversies. Int Urol Nephrol (2010) 0.81
Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). BJU Int (2013) 0.81
A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol (2007) 0.81
First clinical evaluation of a new innovative ureteral access sheath (Re-Trace™): a European study. World J Urol (2013) 0.80
Update on partial nephrectomy and novel techniques. Urol Oncol (2007) 0.80
Current Limitations and Perspectives in Single Port Surgery: Pros and Cons Laparo-Endoscopic Single-Site Surgery (LESS) for Renal Surgery. Diagn Ther Endosc (2010) 0.80
Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene. J Urol (2010) 0.80
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J Clin Oncol (2008) 0.80
Bladder outlet obstruction in men with acute urinary retention: an urodynamic study. World J Urol (2013) 0.80
Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. World J Urol (2014) 0.78
Sex hormone-binding globulin is an independent predictor of biochemical recurrence after radical prostatectomy. J Urol (2012) 0.78
The road to real zero ischemia for partial nephrectomy. J Endourol (2013) 0.78
The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma. J Urol (2013) 0.78
Gender differences in benign renal masses. World J Urol (2013) 0.78
Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy. J Urol (2011) 0.78
Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU Int (2014) 0.78
Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie (2005) 0.78
The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis. J Urol (2013) 0.78
Lower pole stones: prone PCNL versus supine PCNL in the International Cooperation in Endourology (ICE) group experience. World J Urol (2012) 0.78
Use of self-retaining barbed sutures decreases cold ischemia time in open nephron-sparing surgery. Wien Klin Wochenschr (2014) 0.77
The contemporary role of renal tumor biopsy. Eur Urol (2012) 0.77
The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma. DNA Cell Biol (2014) 0.77
Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol (2015) 0.77
Insertion/deletion polymorphism of angiotensin I-converting enzyme gene is linked with chromophobe renal cell carcinoma. Urology (2011) 0.77
A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int (2006) 0.77
Intravesical bacillus Calmette-Guérin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantation. Wien Klin Wochenschr (2013) 0.77
Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology (2013) 0.76
Ureteropelvic junction obstruction. J Urol (2007) 0.76
Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol (2013) 0.76
Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. World J Urol (2014) 0.76
Kidney-sparing surgery for upper tract urothelial cancer. Curr Opin Urol (2015) 0.76
Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. BJU Int (2014) 0.75
Re: Markus J. Bader, Ronald Sroka, Christian Gratzke, et al. Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol 2009;56:65-71. Eur Urol (2009) 0.75
Editorial comment. J Urol (2009) 0.75
Editorial comment on: modified supine versus prone position in percutaneous nephrolithotomy for renal stones treatable with a single percutaneous access: a prospective randomized trial. Eur Urol (2008) 0.75
Surveillance for the management of small renal masses. Adv Urol (2008) 0.75
Is laparoscopic donor nephrectomy the new standard? Nat Clin Pract Urol (2007) 0.75
Editorial comment on: training in percutaneous nephrolithotomy--a critical review. Eur Urol (2008) 0.75
Bladder outlet obstruction (BOO) in men with castration-resistant prostate cancer. BJU Int (2013) 0.75
Editorial for a special issue on kidney transplant. World J Urol (2013) 0.75
Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer? World J Urol (2011) 0.75
Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group". Wien Klin Wochenschr (2014) 0.75